Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling
- PMID: 29121799
- DOI: 10.1142/S0192415X17500938
Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling
Abstract
Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1β (PGC1β), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-β estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
Keywords: Bone Disease; CREB; NFATc1; Osteoclast; PGC1β; Pueraria lobate; Puerariae radix.
Similar articles
-
Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6. Biochem Pharmacol. 2013. PMID: 23928189
-
Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.J Bone Miner Res. 2012 Jun;27(6):1298-1308. doi: 10.1002/jbmr.1576. J Bone Miner Res. 2012. PMID: 22337253
-
CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011. Epub 2015 Jun 21. Bone. 2015. PMID: 26103094
-
Action of RANKL and OPG for osteoclastogenesis.Crit Rev Eukaryot Gene Expr. 2009;19(1):61-72. doi: 10.1615/critreveukargeneexpr.v19.i1.30. Crit Rev Eukaryot Gene Expr. 2009. PMID: 19191757 Review.
-
Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation.Mol Cells. 2017 Oct;40(10):706-713. doi: 10.14348/molcells.2017.0225. Epub 2017 Oct 17. Mol Cells. 2017. PMID: 29047262 Free PMC article. Review.
Cited by
-
The CREB1 inhibitor 666-15 maintains cartilage homeostasis and mitigates osteoarthritis progression.Bone Joint Res. 2024 Jan 2;13(1):4-18. doi: 10.1302/2046-3758.131.BJR-2023-0016.R2. Bone Joint Res. 2024. PMID: 38163445 Free PMC article.
-
Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression.J Bone Metab. 2020 Feb;27(1):53-63. doi: 10.11005/jbm.2020.27.1.53. Epub 2020 Feb 29. J Bone Metab. 2020. PMID: 32190609 Free PMC article.
-
Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis.Antioxidants (Basel). 2021 Feb 9;10(2):265. doi: 10.3390/antiox10020265. Antioxidants (Basel). 2021. PMID: 33572126 Free PMC article. Review.
-
Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis.Front Immunol. 2022 Nov 18;13:1034050. doi: 10.3389/fimmu.2022.1034050. eCollection 2022. Front Immunol. 2022. PMID: 36466887 Free PMC article.
-
Neobavaisoflavone Inhibits Melanogenesis through the Regulation of Akt/GSK-3β and MEK/ERK Pathways in B16F10 Cells and a Reconstructed Human 3D Skin Model.Molecules. 2020 Jun 9;25(11):2683. doi: 10.3390/molecules25112683. Molecules. 2020. PMID: 32527040 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous